Regeneron Pharmaceuticals, Inc. and Sanofi announced the voluntary withdrawal of the supplemental Biologics License Application (sBLA) for Libtayo® (cemiplimab-rwlc) as a second-line treatment for patients with advanced cervical cancer. The decision was made after the companies and the U.S. Food and Drug Administration (FDA) were not able to align on certain post-marketing studies. Discussions with regulatory authorities outside of the U.S. are ongoing.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1,086 USD | -0.86% | +1.35% | +23.61% |
07-12 | UBS Raises Price Target on Regeneron Pharmaceuticals to $1,250 From $1,124, Maintains Buy Rating | MT |
07-11 | Morgan Stanley Trims Price Target on Regeneron Pharmaceuticals to $1,182 From $1,183 | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+23.61% | 117B | |
+20.03% | 126B | |
+22.53% | 27.52B | |
-18.07% | 20.87B | |
-14.01% | 17.01B | |
-14.81% | 16.26B | |
+9.78% | 14.56B | |
-46.10% | 15.09B | |
+52.34% | 13.89B | |
+143.76% | 12.18B |
- Stock Market
- Equities
- REGN Stock
- News Regeneron Pharmaceuticals, Inc.
- Regeneron Pharmaceuticals, Inc. and Sanofi Provides Regulatory Update on Libtayo® (Cemiplimab-Rwlc) in Advanced Cervical Cancer